Allena Pharmaceuticals, Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending March 31, 2022 was $-5 Million (a 6566.67% increase compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) increased by 6478.95%
  • Annual Repayment/Issuance of Debt (Net) for 2021 was $-300 Thousand (a -61.44% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2020 was $-778 Thousand (a 46.52% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $-531 Thousand (a 1.14% increase from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending March 31, 2022 was $-5.23 Million (a 1642.0% increase compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -502.62% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-5.23 Million $-300 Thousand $-642 Thousand $1.3 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of Allena Pharmaceuticals, Inc.

Most recent Repayment/Issuance of Debt (Net)of ALNA including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-5.0
2021 $-0.08 $-0.08 $-0.08 $-0.07 $-0.3
2020 $-0.42 $1.87 $-1.0 $-1.0 $-0.78
2019 $-0.16 $-0.53
2018 $0.0 $0.0 $0.51 $-1.0 $-0.53
2017 $-0.33 $-0.33
2016 $2.5 $1.24 $3.74
2015 $2.5 $2.51

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.